Orally available Emend (aprepitant) from Merck has received FDA approval for use with other antiemetics for the prevention of nausea and vomiting associated with initial and repeated courses of moderately and highly emetogenic chemotherapy. The drug was tested in 866 breast cancer patients who had never before undergone emetogenic chemotherapy and was used in combination with ondansetron and dexamethasone. The new drug is available in 80- and 125-mg capsules with a recommended dose of 125-mg one hour prior to chemotherapy on day one, followed by 80-mg daily on days two and three of the treatment cycle.
Mental Health and CBD: What's the Latest Info
October 27th 2022Drug Topics® is joined by Dr. Alex Capano, Chief Science Officer at Ananda Professional to discuss what CBD is used for mental health, where research should go next, and how to ensure that patients are getting effective CBD products.
Promoting Health Equity and Achieving Pharmacoequity to Ensure Medication Access for All
March 27th 2023Speakers at the 2023 virtual Value-Based Insurance Design Summit discussed government programs and company initiatives to advance health equity, as well as the role of research and advocacy to achieve pharmacoequity.
2 Clarke Drive
Cranbury, NJ 08512